Development and Validation of a Gene Expression Score That Predicts Response to Fulvestrant in Breast Cancer Patients

• Steen Knudsen ,

  * E-mail: steen@medical-prognosis.com

  Affiliation Medical Prognosis Institute, Hørsholm, Denmark

  ⨯
• Thomas Jensen,

  Affiliation Medical Prognosis Institute, Hørsholm, Denmark

  ⨯
• Anker Hansen,

  Affiliation Medical Prognosis Institute, Hørsholm, Denmark

  ⨯
• Wiktor Mazin,

  Affiliations Medical Prognosis Institute, Hørsholm, Denmark, Now at the Department of Clinical Epidemiology at Aarhus University Hospital, Aarhus C, Denmark

  ⨯
• Justin Lindemann,

  Affiliation Astrazeneca UK Limited, Oncology iMED, Alderley Park, Cheshire, United Kingdom

  ⨯
• Irene Kuter,

  Affiliation Massachusetts General Hospital, Massachusetts, Boston, United States of America

  ⨯
• Naomi Laing,

  Affiliation Astrazeneca R&D Boston, Waltham, United States of America

  ⨯
• Elizabeth Anderson

  Affiliations Astrazeneca UK Limited, Oncology iMED, Alderley Park, Cheshire, United Kingdom, Now at Boehringer-Ingelheim RCV GmbH & Co KG, Vienna, Austria

  ⨯